Susan E Creary1,2, Chase Beeman1, Joseph Stanek2, Kathryn King3, Patrick T McGann4, Sarah H O'Brien1,2, Robert I Liem3, Jane Holl5, Sherif M Badawy3,6. 1. Center for Child Health Equity and Outcomes, Research Institute Nationwide Children's Hospital, Columbus, Ohio, USA. 2. Division of Pediatric Hematology/Oncology/BMT, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio, USA. 3. Division of Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. 4. Department of Pediatrics, The Warren Alpert Medical School of Brown University, Hasbro Children's Hospital and Rhode Island Hospital, Providence, Rhode Island, USA. 5. Department of Neurology and Center for Healthcare Delivery Science and Innovation, University of Chicago, Chicago, Illinois, USA. 6. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Abstract
BACKGROUND: Hydroxyurea is the primary treatment for sickle cell anemia (SCA), yet real-world implementation in high-income settings is suboptimal. Variation in prescribed hydroxyurea dose and patient adherence in these settings can both affect actual exposure to hydroxyurea. Quantifying the contributions of hydroxyurea dose and medication adherence to the relationship between hydroxyurea exposure and hematologic parameters could inform strategies to optimize exposure and improve outcomes. PROCEDURE: We evaluated the relationship between hydroxyurea exposure, defined by average prescribed dose and adherence, and hematologic parameters using data from children with SCA who were enrolled in two prospective hydroxyurea adherence studies. Hydroxyurea adherence was assessed by video directly observed therapy or electronic pill bottle and medication administration record. Average prescribed dose was abstracted from prescriptions in patients' electronic medical record. Participants with a hydroxyurea exposure >20 mg/kg/day and ≤20 mg/kg/day were included in the higher and lower exposure groups, respectively. RESULTS: Forty-five participants were included in the analysis (56% male; median age 12 years [range 2-19]; 98% Black). Higher exposed participants (n = 23) were prescribed a higher dose (27.2 vs. 24.4 mg/kg/day, p = .002) and had better adherence (0.92 vs. 0.71, p ≤ .001) compared to lower exposed participants (n = 22). Higher exposure was associated with higher fetal hemoglobin (p = .04) and mean corpuscular volume (p = .02). CONCLUSIONS: Higher hydroxyurea exposure is associated with improved hematologic parameters in the high-income setting and is affected by both prescribed dose and adherence. Future studies are needed to optimize both adherence and hydroxyurea prescribing and confirm that increasing exposure improves clinical outcomes in this setting.
BACKGROUND: Hydroxyurea is the primary treatment for sickle cell anemia (SCA), yet real-world implementation in high-income settings is suboptimal. Variation in prescribed hydroxyurea dose and patient adherence in these settings can both affect actual exposure to hydroxyurea. Quantifying the contributions of hydroxyurea dose and medication adherence to the relationship between hydroxyurea exposure and hematologic parameters could inform strategies to optimize exposure and improve outcomes. PROCEDURE: We evaluated the relationship between hydroxyurea exposure, defined by average prescribed dose and adherence, and hematologic parameters using data from children with SCA who were enrolled in two prospective hydroxyurea adherence studies. Hydroxyurea adherence was assessed by video directly observed therapy or electronic pill bottle and medication administration record. Average prescribed dose was abstracted from prescriptions in patients' electronic medical record. Participants with a hydroxyurea exposure >20 mg/kg/day and ≤20 mg/kg/day were included in the higher and lower exposure groups, respectively. RESULTS: Forty-five participants were included in the analysis (56% male; median age 12 years [range 2-19]; 98% Black). Higher exposed participants (n = 23) were prescribed a higher dose (27.2 vs. 24.4 mg/kg/day, p = .002) and had better adherence (0.92 vs. 0.71, p ≤ .001) compared to lower exposed participants (n = 22). Higher exposure was associated with higher fetal hemoglobin (p = .04) and mean corpuscular volume (p = .02). CONCLUSIONS: Higher hydroxyurea exposure is associated with improved hematologic parameters in the high-income setting and is affected by both prescribed dose and adherence. Future studies are needed to optimize both adherence and hydroxyurea prescribing and confirm that increasing exposure improves clinical outcomes in this setting.
Authors: Martin H Steinberg; Ersi Voskaridou; Abdullah Kutlar; Dimitris Loukopoulos; Mabel Koshy; Samir K Ballas; Oswaldo Castro; Franca Barton Journal: Am J Hematol Date: 2003-02 Impact factor: 10.047
Authors: David C Brousseau; Troy Richardson; Matt Hall; Angela M Ellison; Samir S Shah; Jean L Raphael; David G Bundy; Staci Arnold Journal: Pediatrics Date: 2019-07 Impact factor: 7.124
Authors: Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson Journal: Lancet Date: 2011-05-14 Impact factor: 79.321
Authors: Deepika S Darbari; Mehdi Nouraie; James G Taylor; Carlo Brugnara; Oswaldo Castro; Samir K Ballas Journal: Eur J Haematol Date: 2014-01-30 Impact factor: 2.997
Authors: Elliott Vichinsky; Carolyn C Hoppe; Kenneth I Ataga; Russell E Ware; Videlis Nduba; Amal El-Beshlawy; Hoda Hassab; Maureen M Achebe; Salam Alkindi; R Clark Brown; David L Diuguid; Paul Telfer; Dimitris A Tsitsikas; Ashraf Elghandour; Victor R Gordeuk; Julie Kanter; Miguel R Abboud; Joshua Lehrer-Graiwer; Margaret Tonda; Allison Intondi; Barbara Tong; Jo Howard Journal: N Engl J Med Date: 2019-06-14 Impact factor: 91.245
Authors: S Charache; F B Barton; R D Moore; M L Terrin; M H Steinberg; G J Dover; S K Ballas; R P McMahon; O Castro; E P Orringer Journal: Medicine (Baltimore) Date: 1996-11 Impact factor: 1.889
Authors: Susan E Creary; Mark T Gladwin; Melissa Byrne; Mariana Hildesheim; Lakshmanan Krishnamurti Journal: Pediatr Blood Cancer Date: 2014-01-16 Impact factor: 3.167
Authors: Nicole M Alberts; Sherif M Badawy; Jerlym S Porter; Jane S Hankins; Jason Hodges; Jeremie H Estepp; Chinonyelum Nwosu; Hamda Khan; Matthew P Smeltzer; Ramin Homayouni; Sarah Norell; Lisa Klesges Journal: JMIR Mhealth Uhealth Date: 2020-05-08 Impact factor: 4.773